Molecular and pharmacologic profile of tinzaparin and a comparable low-molecular-weight bacterial sulfaminoheparosan

dc.authoridMa, Qing/0000-0003-0123-9913
dc.authorwosidMa, Qing/A-8012-2008
dc.contributor.authorMaddineni, J
dc.contributor.authorMa, Q
dc.contributor.authorHoppensteadt, DA
dc.contributor.authorDemir, M
dc.contributor.authorManoni, M
dc.contributor.authorCornelli, U
dc.contributor.authorFareed, J
dc.date.accessioned2024-06-12T11:15:47Z
dc.date.available2024-06-12T11:15:47Z
dc.date.issued2004
dc.departmentTrakya Üniversitesien_US
dc.description.abstractLow-molecular-weight heparins (LMWH) represent depolymerized porcine mucosal heparin derivatives, which are commonly used for the management of thrombotic disorders. Because of their widespread usage, the supplies of the raw material namely unfractionated heparin are nearly exhausted. Porcine mucosal tissue is almost exclusively used for the preparation of these agents. Thus, there is a timely need for the production of heparin like drugs from other sources. Fermentation techniques have been used to produce carbohydrates such as dextran and innulin for therapeutic purposes. Bacterial cell wall polysaccharide mimics the linear hexose units, which constitute heparin. Utilizing Escherichia coli cell membranes produced by fermentation technology, chemical sulfation and enzymatic epimerization, sulfamincheparosan type of polymer mimicking the structure of heparin has been produced. These semi-synthetic sulfaminoheparosans exhibit biologic actions comparable to that observed with heparin. The sulfaminoheparosan core can also be degraded to obtain low-molecular-weight (LMW) derivatives mimicking LMWHs. Using this technique, a novel LMW sulfaminoheparosan derivative (Q93C/239) was produced by Inalco, Milan, Italy. To compare this heparin analogue, a LMWH, namely tinzaparin, was used to determine the relative anticoagulant, antiprotease, and molecular profile. Additional studies were carried out to determine the susceptibility of this agent to heparinase-I. These comparative studies exhibited both antiprotease and anticoagulant properties similar to those of tinzaparin. However LMW sulfaminoheparosan resisted heparinase-I digestion at low heparinase-I concentrations. These studies demonstrate that the sulfaminoheparosan derived LMW components exhibit similar molecular and anticoagulant profile as tinzaparin and warrant additional preclinical and clinical development to determine their potential usefulness as antithrombotic agents.en_US
dc.identifier.doi10.1177/107602960401000105
dc.identifier.endpage37en_US
dc.identifier.issn1076-0296
dc.identifier.issn1938-2723
dc.identifier.issue1en_US
dc.identifier.pmid14979402en_US
dc.identifier.scopus2-s2.0-2142655746en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage27en_US
dc.identifier.urihttps://doi.org/10.1177/107602960401000105
dc.identifier.urihttps://hdl.handle.net/20.500.14551/24071
dc.identifier.volume10en_US
dc.identifier.wosWOS:000188438600005en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSage Publications Incen_US
dc.relation.ispartofClinical And Applied Thrombosis-Hemostasisen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectSulfaminoheparosanen_US
dc.subjectLow-Molecular-Weight Heparinen_US
dc.subjectUnfractionated Heparinen_US
dc.subjectAntiproteaseen_US
dc.subjectAntithromboticen_US
dc.subjectAnticoagulanten_US
dc.subjectEscherichia-Coli K5en_US
dc.subjectCapsular Polysaccharideen_US
dc.subjectHeparin Pentasaccharideen_US
dc.subjectThrombosisen_US
dc.subjectSulfationen_US
dc.subjectBiosynthesisen_US
dc.titleMolecular and pharmacologic profile of tinzaparin and a comparable low-molecular-weight bacterial sulfaminoheparosanen_US
dc.typeArticleen_US

Dosyalar